Health technology assessment: oncology drugs with orphan designation as an example
نویسنده
چکیده
Background Since (limited) health care resources have to be invested efficiently, HTA/ health technology assessment is applied ever more often in many health care systems for ‘rational decision-making’. Around 40% to 50% of all drugs with orphan designation are high-priced oncology drugs. Within EUnetHTA (an EU-supported project) a work package deals with the pre-coverage exchange of early assessments among European countries and the collaboration on projects for further generation of evidence.
منابع مشابه
Pricing and reimbursement of novel oncology drugs in Sweden
We read with great interest the article by Cohen and Felix (1) concerning reimbursement restrictions on orphan drugs. We agree with their concerns that orphan drugs are often met with reimbursement restrictions, but data on the relationship between orphan status and pricing and reimbursement outcomes are scarce. Furthermore, regional disparities within Europe are likely to be significant, contr...
متن کاملOrphan Drugs Assessment in Germany: A Comparison with Other International HTA Agencies.
• Germany did not issue any negative recommendations for any of the 20 Orphan Drug assessments – However, 7 assessments (35%) where the additional benefit was not quantifiable would have been negative if the products did not have an EMA Orphan Drug designation and a legislated «implicit additional clinical benefit» – Potential changes to the German drug assessment mechanism could impact this on...
متن کاملAre products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
BACKGROUND Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare cancers. In order to provide more insights in drugs for rare neoplastic disorders that are under development and to better understand the role of orphan designation in the develop...
متن کاملThe correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
BACKGROUND The aim of this study was to review and compare types of reimbursement recommendations for orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement status of these drugs in the corresponding countries. Separate calculations were also performed for three sub-groups: ultra-orphan drugs, oncology orphan drugs and other (non-ultra, non-oncol...
متن کاملDeterminants of orphan drugs prices in France: a regression analysis
BACKGROUND The introduction of the orphan drug legislation led to the increase in the number of available orphan drugs, but the access to them is often limited due to the high price. Social preferences regarding funding orphan drugs as well as the criteria taken into consideration while setting the price remain unclear. The study aimed at identifying the determinant of orphan drug prices in Fra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 5 شماره
صفحات -
تاریخ انتشار 2010